<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35521889</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>ATXN2 intermediate expansions in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2671</StartPage><EndPage>2676</EndPage><MedlinePgn>2671-2676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac167</ELocationID><Abstract><AbstractText>Intermediate CAG (polyQ) expansions in the gene ataxin-2 (ATXN2) are now recognized as a risk factor for amyotrophic lateral sclerosis. The threshold for increased risk is not yet firmly established, with reports ranging from 27 to 31 repeats. We investigated the presence of ATXN2 polyQ expansions in 9268 DNA samples collected from people with amyotrophic lateral sclerosis, amyotrophic lateral sclerosis with frontotemporal dementia, frontotemporal dementia alone, Lewy body dementia and age matched controls. This analysis confirmed ATXN2 intermediate polyQ expansions of &#x2265;31 as a risk factor for amyotrophic lateral sclerosis with an odds ratio of 6.31. Expansions were an even greater risk for amyotrophic lateral sclerosis with frontotemporal dementia (odds ratio 27.59) and a somewhat lesser risk for frontotemporal dementia alone (odds ratio 3.14). There was no increased risk for Lewy body dementia. In a subset of 1362 patients with amyotrophic lateral sclerosis with complete clinical data, we could not confirm previous reports of earlier onset of amyotrophic lateral sclerosis or shorter survival in 25 patients with expansions. These new data confirm &#x2265;31 polyQ repeats in ATXN2 increase the risk for amyotrophic lateral sclerosis, and also for the first time show an even greater risk for amyotrophic lateral sclerosis with frontotemporal dementia. The lack of a more aggressive phenotype in amyotrophic lateral sclerosis patients with expansions has implications for ongoing gene-silencing trials for amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewan</LastName><ForeName>Ramita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-6985-0658</Identifier><AffiliationInfo><Affiliation>Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalgard</LastName><ForeName>Clifton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keagle</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shankaracharya</LastName><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Redondo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciaon Hospital 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke (NINDS), NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Therapeutic Development Branch, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20850, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR025774</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ataxin-2</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">polyQ expansion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35521889</ArticleId><ArticleId IdType="pmc">PMC9890463</ArticleId><ArticleId IdType="doi">10.1093/brain/awac167</ArticleId><ArticleId IdType="pii">6581628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scoles &#xa0;DR, Pulst &#xa0;SM. Spinocerebellar ataxia type 2. Adv Exp Med Biol. 2018;1049:175&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">29427103</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker &#xa0;LA, Gitler &#xa0;AD. Ataxin-2 is droppin&#x2019; some knowledge. Neuron. May. 2018;98:673&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">29772196</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker &#xa0;LA, Huang &#xa0;B, Bieri &#xa0;G, et al. &#xa0;Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden &#xa0;AC, Kim &#xa0;HJ, Hart &#xa0;MP, et al. &#xa0;Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero &#xa0;G, Pugliatti &#xa0;M, Marrosu &#xa0;F, et al. &#xa0;ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiol Aging. 2015;36:2906.e1&#x2013;2906.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5193218</ArticleId><ArticleId IdType="pubmed">26208502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio &#xa0;A, Calvo &#xa0;A, Moglia &#xa0;C, et al. &#xa0;ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology. 2015;84:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">25527265</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme &#xa0;P, Veldink &#xa0;JH, van Blitterswijk &#xa0;M, et al. &#xa0;Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76:2066&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;MD, Gomes &#xa0;J, Cashman &#xa0;NR, Little &#xa0;J, Krewski &#xa0;D. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS&#x2013;A systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9:e105534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141758</ArticleId><ArticleId IdType="pubmed">25148523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero &#xa0;W, Shatunov &#xa0;A, Stahl &#xa0;D, et al. &#xa0;ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging. 2017;51:178.e1&#x2013;178.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuenschwander &#xa0;AG, Thai &#xa0;KK, Figueroa &#xa0;KP, Pulst &#xa0;SM. Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: A meta-analysis. JAMA Neurol. 2014;71:1529&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939089</ArticleId><ArticleId IdType="pubmed">25285812</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia &#xa0;R, Sabir &#xa0;MS, Bandres-Ciga &#xa0;S, et al. &#xa0;Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946812</ArticleId><ArticleId IdType="pubmed">33589841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan &#xa0;R, Chia &#xa0;R, Ding &#xa0;J, et al. &#xa0;Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2021;109:448&#x2013;460.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864894</ArticleId><ArticleId IdType="pubmed">33242422</ArticleId></ArticleIdList></Reference><Reference><Citation>Erikson &#xa0;GA, Bodian &#xa0;DL, Rueda &#xa0;M, et al. &#xa0;Whole-genome sequencing of a healthy aging cohort. Cell. 2016;165:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860090</ArticleId><ArticleId IdType="pubmed">27114037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci &#xa0;L. The Baltimore Longitudinal Study of Aging (BLSA): A 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci. 2008;63:1416&#x2013;1419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004590</ArticleId><ArticleId IdType="pubmed">19126858</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko &#xa0;E, Deshpande &#xa0;V, Schlesinger &#xa0;F, et al. &#xa0;Expansion Hunter: A sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35:4754&#x2013;4756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853681</ArticleId><ArticleId IdType="pubmed">31134279</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton &#xa0;AE, Majounie &#xa0;E, Waite &#xa0;A, et al. &#xa0;A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth &#xa0;D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27&#x2013;38.</Citation></Reference><Reference><Citation>Saxon &#xa0;JA, Thompson &#xa0;JC, Harris &#xa0;JM, et al. Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:1304&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677467</ArticleId><ArticleId IdType="pubmed">33055142</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh &#xa0;ME, Dammer &#xa0;EB, Dai &#xa0;J, et al. &#xa0;A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10:48&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino &#xa0;E, Mancini &#xa0;C, Boschi &#xa0;S, et al. &#xa0;ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol Aging. 2019;73:231.e7&#x2013;231.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30342763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross &#xa0;OA, Rutherford &#xa0;NJ, Baker &#xa0;M, et al. &#xa0;Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20:3207&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140823</ArticleId><ArticleId IdType="pubmed">21610160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski &#xa0;LA, Hall &#xa0;AC, Mekhail &#xa0;K. Ataxin-2: From RNA control to human health and disease. Genes (Basel). 2017;8:157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485521</ArticleId><ArticleId IdType="pubmed">28587229</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong &#xa0;W, Paul &#xa0;S, Figueroa &#xa0;KP, et al. &#xa0;Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet. 2015;11:e1005182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406435</ArticleId><ArticleId IdType="pubmed">25902068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang &#xa0;Y, Halliday &#xa0;GM, Kiernan &#xa0;MC, Tan &#xa0;RH. TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology. 2019;93:e1748&#x2013;e1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">31619481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;K, Daigle &#xa0;JG, Cunningham &#xa0;KM, et al. &#xa0;Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>